Extracellular Volume Associated With New-Onset Atrial Fibrillation

Atrial Fibrillation Clinical Trial

Official title:

Cardiac MRI Extracellular Volume Associated With New-Onset Atrial Fibrillation in Patients With ST-Segment Elevation Myocardial Infarction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06447857
• Other study ID #: XYFY2024-KL189-01
• Status: Completed
• Start date: January 1, 2020
• Est. completion date: May 31, 2024

Study information

• Verified date: May 2024
• Source: The Affiliated Hospital of Xuzhou Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Left ventricular fibrosis is strongly associated with atrial fibrillation (AF). However, the relationship between LV fibrosis and new-onset AF (NOAF) after ST-segment elevation myocardial infarction (STEMI) is currently unknown. This study was to investigate the relationship between different regions of ECV and NOAF during the acute phase of STEMI. ECV in integral (integral ECV), non-myocardial infarction region (NMI-ECV) and myocardial infarction region (MI-ECV) was obtained by CMR.

Description:

This retrospective study included patients diagnosed with STEMI at the Affiliated Hospital of Xuzhou Medical University. All patients underwent CMR during hospitalization, which included T1 mapping sequences. The blood sampling was collected within 24 hours of the CMR examination. Inclusion criteria: 1. Successful pPCI (TIMI flow ≥ 2) within 12 hours after symptom onset; 2. Admission to the cardiac care unit for continuous electrocardiogram (ECG) monitoring after pPCI. Exclusion criteria: 1. Poor image quality; 2. History of myocardial infarction; 3. History of atrial fibrillation; 4. Malignancy, or inflammatory disease; 5. Severe valvular heart disease; 6. Thyroid dysfunction. NOAF was defined as post-admission atrial fibrillation without a history of atrial fibrillation. ECG monitoring revealed a suspicious rhythm during admission, and an immediate 12-lead ECG confirmed NOAF. Infarct-related arteries (IRA) were recorded based on CAG findings. ECV in integral (integral ECV), non-myocardial infarction region (NMI-ECV) and myocardial infarction region (MI-ECV) was obtained by CMR.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 589
• Est. completion date: May 31, 2024
• Est. primary completion date: May 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Successful pPCI (TIMI flow = 2) within 12 hours after symptom onset

• Admission to the cardiac care unit for continuous electrocardiogram (ECG) monitoring after pPCI

Exclusion Criteria:

• Poor image quality

• History of myocardial infarction

• History of atrial fibrillation

• Malignancy, or inflammatory disease

• Severe valvular heart disease

• Thyroid dysfunction

Related Conditions & MeSH terms

• Atrial Fibrillation
• Cardiac Magnetic Resonance
• Extracellular Volume Overload
• Infarction
• Myocardial Infarction

Intervention

Other:
• Cardiac MRI
This retrospective study included patients diagnosed with STEMI at the Affiliated Hospital of Xuzhou Medical University. All patients underwent CMR.

Locations

Country	Name	City	State
China	The Affiliated Hospital of Xuzhou Medical University	Xuzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
The Affiliated Hospital of Xuzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary endpoint events included new-onset atrial fibrillation	NOAF was defined as post-admission atrial fibrillation without a history of atrial fibrillation. ECG monitoring revealed a suspicious rhythm during admission, and an immediate 12-lead ECG confirmed NOAF.	during hospitalization (assessed up to 10 days)